Buchumschlag

Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy

Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pottier, Charles Albert (VerfasserIn) , Fresnais, Margaux (VerfasserIn) , Longuespée, Rémi (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 March 2020
In: Cancers
Year: 2020, Jahrgang: 12, Heft: 3
ISSN:2072-6694
DOI:10.3390/cancers12030731
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers12030731
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/12/3/731
Volltext
Verfasserangaben:Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée and Nor Eddine Sounni

MARC

LEADER 00000caa a2200000 c 4500
001 1726248631
003 DE-627
005 20220818170230.0
007 cr uuu---uuuuu
008 200805s2020 xx |||||o 00| ||eng c
024 7 |a 10.3390/cancers12030731  |2 doi 
035 |a (DE-627)1726248631 
035 |a (DE-599)KXP1726248631 
035 |a (OCoLC)1341352044 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pottier, Charles Albert  |d 1755-1829  |e VerfasserIn  |0 (DE-588)12885099X  |0 (DE-627)707083966  |0 (DE-576)297363026  |4 aut 
245 1 0 |a Tyrosine kinase inhibitors in cancer  |b breakthrough and challenges of targeted therapy  |c Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée and Nor Eddine Sounni 
264 1 |c 20 March 2020 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 05.08.2020 
520 |a Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer cell growth and metastasis. During the last two decades, several molecules targeting RTKs were used in oncology as a first or second line therapy in different types of cancer. However, their effectiveness is limited by the appearance of resistance or adverse effects. In this review, we summarize the main features of RTKs and their inhibitors (RTKIs), their current use in oncology, and mechanisms of resistance. We also describe the technological advances of artificial intelligence, chemoproteomics, and microfluidics in elaborating powerful strategies that could be used in providing more efficient and selective small molecules inhibitors of RTKs. Finally, we discuss the interest of therapeutic combination of different RTKIs or with other molecules for personalized treatments, and the challenge for effective combination with less toxic and off-target effects. 
650 4 |a cancer 
650 4 |a oncology 
650 4 |a pharmacology 
650 4 |a tyrosine kinase inhibitors 
700 1 |a Fresnais, Margaux  |e VerfasserIn  |0 (DE-588)1190043157  |0 (DE-627)1668720108  |4 aut 
700 1 |a Longuespée, Rémi  |e VerfasserIn  |0 (DE-588)113707146X  |0 (DE-627)89404690X  |0 (DE-576)491093179  |4 aut 
773 0 8 |i Enthalten in  |t Cancers  |d Basel : MDPI, 2009  |g 12(2020,3) Artikel-Nummer 731, 17 Seiten  |h Online-Ressource  |w (DE-627)614095670  |w (DE-600)2527080-1  |w (DE-576)313958548  |x 2072-6694  |7 nnas  |a Tyrosine kinase inhibitors in cancer breakthrough and challenges of targeted therapy 
773 1 8 |g volume:12  |g year:2020  |g number:3  |g extent:17  |a Tyrosine kinase inhibitors in cancer breakthrough and challenges of targeted therapy 
856 4 0 |u https://doi.org/10.3390/cancers12030731  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2072-6694/12/3/731  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200805 
993 |a Article 
994 |a 2020 
998 |g 113707146X  |a Longuespée, Rémi  |m 113707146X:Longuespée, Rémi  |d 910000  |d 910100  |e 910000PL113707146X  |e 910100PL113707146X  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 1190043157  |a Fresnais, Margaux  |m 1190043157:Fresnais, Margaux  |p 2 
999 |a KXP-PPN1726248631  |e 3735687628 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1726248631","language":["eng"],"note":["Gesehen am 05.08.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Tyrosine kinase inhibitors in cancer","subtitle":"breakthrough and challenges of targeted therapy","title_sort":"Tyrosine kinase inhibitors in cancer"}],"person":[{"family":"Pottier","given":"Charles Albert","roleDisplay":"VerfasserIn","display":"Pottier, Charles Albert","role":"aut"},{"display":"Fresnais, Margaux","roleDisplay":"VerfasserIn","role":"aut","family":"Fresnais","given":"Margaux"},{"family":"Longuespée","given":"Rémi","display":"Longuespée, Rémi","roleDisplay":"VerfasserIn","role":"aut"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisher":"MDPI","publisherPlace":"Basel"}],"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"pubHistory":["1.2009 -"],"part":{"volume":"12","text":"12(2020,3) Artikel-Nummer 731, 17 Seiten","extent":"17","year":"2020","issue":"3"},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Tyrosine kinase inhibitors in cancer breakthrough and challenges of targeted therapyCancers","note":["Gesehen am 27.05.2020"],"recId":"614095670","language":["eng"],"title":[{"title":"Cancers","title_sort":"Cancers"}]}],"physDesc":[{"extent":"17 S."}],"id":{"eki":["1726248631"],"doi":["10.3390/cancers12030731"]},"origin":[{"dateIssuedDisp":"20 March 2020","dateIssuedKey":"2020"}],"name":{"displayForm":["Charles Pottier, Margaux Fresnais, Marie Gilon, Guy Jérusalem, Rémi Longuespée and Nor Eddine Sounni"]}} 
SRT |a POTTIERCHATYROSINEKI2020 

Ähnliche Einträge